Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial

Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial

Abstract Neoadjuvant PD-1 inhibitor is promising in cutaneous melanoma but remains unknown in acral melanoma (AM). This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1 toripalimab (...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiayong Liu, Xuan Wang, Zhongwu Li, Shunyu Gao, Lili Mao, Jie Dai, Caili Li, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Yumei Lai, Zhichao Tan, Bin Lian, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Juan Li, Jun Guo, Lu Si
Format: Article
Language:English
Published: Nature Publishing Group 2024-11-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-024-02029-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-024-02029-2

Similar Items